Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003263 · ClinicalTrials.gov registry record · Phase 1

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

A Phase 1 study of Malignant Mesothelioma, sponsored by Fox Chase Cancer Center.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
3
Study locations

NCT00003263: Completed Phase 1 study of Malignant Mesothelioma, sponsored by Fox Chase Cancer Center.

NCT00003263 is a Phase 1 study of Malignant Mesothelioma that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 6 participants, below the 76-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003263, a Phase 1 study of Malignant Mesothelioma, has completed, sponsored by Fox Chase Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy, radiation therapy, and interferon alfa may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of cisplatin plus interferon alfa followed by surgery and interferon alfa plus radiation therapy in treating patients with malignant pleural mesothelioma.

Conditions Studied

Malignant Mesothelioma

Interventions

  • DRUG cisplatin
  • RADIATION radiation therapy
  • BIOLOGICAL recombinant interferon alfa
  • PROCEDURE surgical procedure

Study Locations (3)

Louisiana

  • Office of S. Terry Kraus - Marrero

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Virginia

  • Virginia Oncology Associates - Newport News

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 1996-08
Est. Completion 2000-11
Phase Phase 1
Fox Chase Cancer Center

183 total trials

What the finished NCT00003263 record still lists

NCT00003263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 76-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.

NCT00003263 reports a single indexed study location in Louisiana, Pennsylvania, Virginia.

Frequently Asked Questions

What is clinical trial NCT00003263 about?

NCT00003263 is a clinical study titled "Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy, radiation therapy, and inter...

What is the current status of trial NCT00003263?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 1996-08. Estimated completion is 2000-11.

What conditions does trial NCT00003263 study?

This clinical trial studies the following conditions: Malignant Mesothelioma.

What interventions are being tested in trial NCT00003263?

The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), recombinant interferon alfa (BIOLOGICAL), surgical procedure (PROCEDURE).

Who is sponsoring clinical trial NCT00003263?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003263 being conducted?

This trial has 3 study locations across Louisiana, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Mesothelioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003263's enrollment target sits among peer trials

6 12th of 11 the lowest of 11 other Malignant Mesothelioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00003263, the US trial registry maintained by the National Library of Medicine. NCT00003263 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.